Renatus

To counteract the rapid depletion of plasma membrane cholesterol caused by #HPßCD, Renatus is dedicated to generating safe and effective cholesterol modulators aimed at enhancing patients' quality of life. Renatus has pioneered technology that cross-links gamma-cyclodextrin monomers to create oligomers that form a highly stable complex with cholesterol, without depleting it from the plasma membrane. The lead asset, RN-005, is currently in preclinical development, employing patented methods targeting conditions such as chronic kidney disease and neurodegenerative diseases caused by proteinopathies. 📚 Read more here 👉 https://lnkd.in/e4qaNnPx. #pharma #biotech #cyclodextrin #monomers #oligomers #cholesterol #plasmamembrane #kidneydisease #neurodegenerative

Cholesterol metabolism plays a pivotal role in the pathogenesis and progression of numerous diseases, impacting health from early adulthood through advanced age. Cholesterol is essential for various physiological functions, including cell membrane integrity, hormone production, and bile acid formation. However, imbalances in cholesterol metabolism can lead to pathological conditions. Aging, genetic predispositions, dietary habits, and lifestyle factors significantly influence cholesterol homeostasis. With advancing age, the body’s ability to regulate cholesterol levels diminishes, increasing the risk of developing cardiovascular diseases, neurodegenerative disorders like Alzheimer’s disease, chronic kidney disease, and even certain types of cancer. Understanding the complex interplay between cholesterol metabolism and these factors is crucial for devising effective therapeutic interventions. Despite the critical role of cholesterol in disease progression, there is a notable lack of medicines that can effectively modulate cellular cholesterol metabolism. Current treatments, such as statins, primarily focus on lowering plasma cholesterol levels, which, while beneficial, do not adequately address the underlying cellular dysregulation: impaired cholesterol efflux, abnormal cholesterol distribution and accumulation, oxidative stress, mitochondrial dysfunction, and inflammatory responses. This gap in treatment options underscores the necessity for innovative approaches that target cellular cholesterol homeostasis. By developing therapies that can precisely modulate cholesterol at the cellular level, we can potentially mitigate the onset and progression of cholesterol-related diseases, offering patients more comprehensive and effective management strategies. At Renatus, we are at the forefront of this innovative approach. Our research and development efforts are dedicated to finding novel, safe cyclodextrins (CDs) and leveraging their unique properties to target various diseases and . Our proprietary #CHOLYSER™ CDs exhibit exceptional abilities to preferentially and effectively encapsulate non-membranous cholesterol. Compared to #HPβCD (hydroxypropyl-beta-cyclodextrin), which is under clinical trials for several diseases, CHOLYSER™ CDs offer not only improved cholesterol-lowering effects but also superb safety profiles, providing a powerful means of modulating cholesterol metabolism with a wider therapeutic window. By focusing on these advanced "cholesterol modulators", or "cholesterol-lowering agents", we aim to address the unmet medical need for effective cholesterol intervention, significantly improving patient outcomes and advancing the treatment of cholesterol-related diseases. https://lnkd.in/gKB74AcS #Renatus #CHOLYSER #Cholesterol #Statin #CholesterolIntervention

Happy to announce that Renatus won Impact Award in 2024 Merck's Advance Biotech Grant Program!

Excited to join the BioNeex BD platform as a drug candidate provider.

Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, today announced the registration of a U.S. patent No. 11931376 entitled “METHODS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.”   Dysregulated renal cholesterol metabolism can contribute to the progression of chronic kidney disease (CKD). Treatment with RN-005 in preclinical models of CKD has shown to effectively reverse cholesterol and triglycerides accumulation and promote normalization of cholesterol metabolism pathways in the kidney. Modulation of cholesterol metabolism in the kidney by RN-005 exerts significant renoprotective effects, lowering serum creatinine and BUN levels and albuminuria, which are key indicators of kidney function and damage, respectively.   Heegon Kim, CEO of Renatus, commented: “Cholesterol metabolism plays crucial roles in the development of chronic kidney disease, making it a new promising therapeutic target. To date, however, there is no drug that can promote cholesterol metabolism and efflux in the kidney. The patent reinforces the value of our cholesterol modulator RN-005 as a potential treatment for chronic kidney disease.” #Chronickidneydisease #Diabetickidneydisease #cholesterol #metabolism #RN005 #Renatus https://lnkd.in/gBBCdMvt

Renatus Inc., a pharmaceutical company developing cholesterol modulators for the treatment of cholesterol-driven diseases, was introduced on Pax Economy TV's 'Close-Up of Business', which introduces promising small businesses based in South Korea.   Renatus’ proprietary cholesterol modulator, RN-005, has shown to promote cholesterol metabolism and mediate cholesterol efflux in varying disease models including chronic kidney disease and atherosclerosis, wherein cholesterol metabolism plays critical roles in their pathogenesis. It has successfully secured domestic and international patents for the drug candidate and its use for the treatment of cholesterol-driven diseases. Dysregulated cholesterol homeostasis and its accumulation is commonly observed in chronic kidney disease (CKD), which affects 1 in 8 adults worldwide. RN-005 treatment in CKD models demonstrated its renoprotective effects, as it significantly reduced blood creatinine, BUN levels and albuminuria. Renatus is preparing for a clinical trial for chronic kidney disease in both humans and companion animals. Heegon Kim, CEO of Renatus, commented: “To date, no medicine has been developed to normalize cholesterol metabolism and promote its efflux in our body. Our goal is to develop a safe and effective cholesterol modulator so that it can be used to treat various cholesterol-driven diseases including chronic kidney disease, and thereby improve the quality of life of the patients.” #Renatus #cyclodextrin #RN005 #cholesterolmodulator #interview #chronickidneydisease #animalhealth

Renatus Inc. today presented data on RN-005, a cholesterol metabolism modulator, in two preclinical chronic kidney disease models at the 2023 Scale-up Challenge Lab Conference. Renatus Inc., a pharma company focusing on cholesterol metabolism modulators that can address dysregulated cholesterol homeostasis in varying diseases, today announced preclinical data on RN-005 in diabetic nephropathy (DN) and focal segmental glomerulosclerosis (FSGS) models at the 2023 Scale-up Challenge Lab Conference in Incheon, South Korea. Cholesterol accumulation and dysregulated cholesterol homeostasis is commonly observed in the kidney of patients with chronic kidney disease (CKD), which affects more than 10% of the general population worldwide. Excessive cholesterol accumulation causes lipotoxicity, which can ultimately lead to kidney dysfunction and failure. Unfortunately, there is no drug available in the market that can directly target intracellular cholesterol and promote its efflux. Renatus' lead candidate, RN-005, is a novel synthetic cyclodextrin that can modulate cholesterol metabolism and promote its efflux. "In both chronic kidney disease models, RN-005 showed consistent renoprotective effects by decreasing blood creatinine and BUN levels and albuminuria. We also found that RN-005 effectively lowered renal cholesterol and triglycerides contents, which are significantly eleveated in the disease model," said Heegon Kim, CEO of Renatus. "These findings suggest that targeting renal cholesterol, not systemic cholesterol, can provide a new therapeutic option for the treatment of chronic kidney disease." New data also highlighted that RN-005 exerted renoprotective effects at a much lower dose than hydroxypropyl-β-cyclodextrin (HPβCD), which is being tested in clinical trials for the treatment of varying cholesterol-driven diseases. Due to the low dose requirement, RN-005 is being developed for subcutaneous formulation, as opposed to HPβCD that requires high dose administration and therefore should be infused over hours, for both human and companion animals. #cyclodextrin #RN005 #chronickidneydisease #animalhealth #veterinarymedicine #diabetickidneydisease #focalsegmentalglomerulosclerosis